Heterogeneity of Unilateral Multiple Breast Cancer: Implications for Biomarker Testing

Article Sidebar

PDF
Published: Sep 20, 2014
DOI: https://doi.org/10.31524/bkkmedj.2014.09.003

Main Article Content

Shanop Shuangshoti, MD
Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand , Gene RPO Center, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Ratchaya Sawatdee, MD
Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Anantnuch Sakapibunnan, MD
Section of Anatomical Pathology, The National Cancer Institute, Department of Medical Services, Ministry of Public Health, Bangkok, Thailand.
Wipawee Kittigowit, MD
Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Somruetai Shuangshoti, MD
The Institute of Pathology, Department of Medical Services, Ministry of Public Health, Bangkok, Thailand.
Benjaporn Chaiwun, MD
Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Pichet Sampatanukul, MD
Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Apiwat Mutirangura, MD
Center for Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Paul Scott Thorner, MD, PhD
Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand , Department of Laboratory Medicine, Hospital for Sick Children and University of Toronto, Toronto, Canada.

Abstract

OBJECTIVE:
This study was to re-examine the usefulness of biomarker assays in all multiple tumors in the same breast, and to evaluate the genetic heterogeneity of unilateral multiple breast carcinoma.

MATERIALS AND METHODS:
All of the cases met the criteria for synchronous multicentric breast carcinomas. Tumors were either 5 cm apart or within the different breast quadrants, with no identifiable connection between lesions, and were diagnosed at the same time for an individual patient.

RESULTS:
In the present study, 32 tumors from 15 patients with synchronous unilateral breast cancer were immunostained for estrogen receptor (ER), progesterone receptor (PR), and HER-2, and also underwent microsatellite analysis using 10 polymorphic markers. The ER and PR expression profile was similar in all tumors from the same patient. Discordant HER-2 immunoreactivity was found and confirmed by HER-2 FISH test in one case, and heterogeneity in the microsatellite pattern was observed in 6 patients.

CONCLUSION:
With the routinely-used biomarkers (ER, PR, and HER-2), heterogeneity was minimal, however, with more frequent differences noted at the genetic levels.

Article Details

How to Cite
1.
Shuangshoti S, Sawatdee R, Sakapibunnan A, Kittigowit W, Shuangshoti S, Chaiwun B, Sampatanukul P, Mutirangura A, Thorner PS. Heterogeneity of Unilateral Multiple Breast Cancer: Implications for Biomarker Testing. BKK Med J [internet]. 2014 Sep. 20 [cited 2026 Oct. 23];8(1):17. available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/219720
Issue
Vol. 8 (2014): September
Section
Original Article
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This article is published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). You may copy and redistribute the material for noncommercial purposes, provided that appropriate credit is given and a link to the license is included. Modified versions may not be distributed under this license.

License: https://creativecommons.org/licenses/by-nc-nd/4.0/